公司概况与整体业绩 * 航材股份2025年前三季度实现营业收入20.39亿元，同比下降7%[4] * 公司净利润为4亿元，同比下降8.23%[4] * 公司全年完成财务预算目标有压力，但仍有希望[3][22] 各业务板块财务表现 **收入情况** * 透明件事业部收入2.1亿元，同比下降2300万元，降幅约9%[4] * 橡胶与密封材料销售收入6.8亿元，与去年同期基本持平[4] * 高温合金母合金销售收入6.56亿元，同比下降6200万元，降幅8%[4] * 铸造钛合金销售收入44.89亿元，同比下降6700万元，降幅12%[4] **毛利率情况** * 透明件毛利率约为40%，较去年略有下降，主要受台州新生产线费用增加影响[5] * 橡胶产业毛利率约为57%，较去年的55%有所提升[5] * 高温合金母合金毛利率约为14%，较去年的13%略有提升[5] * 铸造钛合金毛利率在12%至18%之间，比去年略有增加，但仍面临降价压力[5] 钛合金业务深度分析 **下游市场分布与表现** * 航空领域收入接近7000万元，同比下降40%[6] * 航发领域收入2.2亿元，与去年同期基本持平[6] * 航天领域收入4600万元，同比下降30%[6] * 出口市场前三季度收入1.5亿元，同比增长接近30%[6] * 国内民机（主要针对商发）收入1500万元，同比增长40%[6] **运营与战略** * 收回浙江钛合金公司股权后，并未直接提升国外市场份额，赛峰集团等客户仍维持长期合作协议[7] * 公司希望未来铸造钛合金的毛利率达到30%以上，需提高产能利用率[9] * 铸造钛合金设计产能接近6亿元，但实际产量仅在两个多亿左右[9][10] 高温合金业务深度分析 **销售结构与产能** * 今年前三季度高温合金额外销售1570吨，其中单晶7吨、等轴1100吨、定向350吨、大型铸件100多吨[11] * 加工方面总量接近1500吨，其中单晶200吨、等轴100吨、定向40多吨、粉末1500吨[11] * 高温合金熔炼总产能可达5000-6000吨，以满足未来需求增长[14] **价格与知识产权** * 高温合金额外价格总体稳定，以镍价为主导[12] * 公司正在推进知识产权转让工作，已完成原来6个母牌号转让，不会对现有产能形成冲击[13] 透明件业务分析 **产品结构与价格** * 透明件业务中歼击机销售收入为1.95亿元，占比显著提升[17] * 直升机销售收入为1600万元，占比持续降低[17] * 成都方向占透明件业务大约40%至50%，其主力型号价格从去年下半年开始有所上涨[17] **重大项目进展** * 大飞机风挡玻璃项目正积极推进，技术水平不逊于海外竞争对手，但民用飞机适航要求更苛刻，时间周期较长[18] 橡胶密封业务分析 **业务构成与应用** * 橡胶密封业务是重要利润来源，产品包括弹性元件（上半年销售额1.4亿元）、减震器（5000万元）、密封剂（2亿元）及其他橡胶胶料（5000万元）[19] * 产品广泛应用于军机和民机，包括大型无人机如腾顿双尾蝎、翼龙系列、彩虹系列等[19] **民机市场展望** * 在民用飞机橡胶密封件方面，部分产品正在走认证过程，预计未来实现国产替代后的价值量约为300万元左右[21] 其他重要运营信息 **技术改进与成本控制** * 公司持续改进熔炼方法和加工过程，母合金的收得率大约在80%左右[16] * 民品中返回料的应用比例约为30%，军品返回料的利用还在研究阶段[16] * 公司探索提升钢铁高温材料利润率的措施，目前该项业务毛利率尚未显著提高[15] **产能建设项目** * 顺义橡胶与密封材料项目进展最快，厂房已封顶，希望明年底具备逐步搬迁设备条件[24] * 透明件的大飞机挡风玻璃研制项目因科研类性质有所延期[24] **未来规划与股东情况** * 公司正在制定十五五规划，预计明年上半年需求会更加明确[23] * 明年员工持股到期，公司计划在明年初形成方案，避免集中减持[26] 行业与市场动态 **燃气轮机市场** * 公司高温合金母合金主要跟踪国内市场，与上燃等五六家企业已签订合同[8] * 国内燃气轮机高温合金市场增长较快，但绝对数量与航空发动机相比仍然较小[27] * 公司主要精力放在国内燃气轮机业务开发，同时也接触国外客户，但需要三方合作推动[28] **整体行业环境** * 今年整个军工系统的情况并不乐观[22]

机构：中银国际 研究员：Lawrence LAU/Rainey DAI Further decline in revenue / earnings at well services segment. COSL's earnings grew 16% QoQ to RMB1.25bn in 3Q25. Margin improvement and lower effective tax rate were the key growth drivers. We expect its earnings to drop 17% QoQ in 4Q25 as it is likely to book more costs in 4Q of a year. We increase our 2025-27 earnings forecast by 8-10% mainly to reflect the decline in effective tax rate. We reiterate our BUY calls and raise our target price for its H shares to HK$9.70 ...

Modine Manufacturing Company (NYSE:MOD) Q2 2026 Earnings Call October 29, 2025 11:00 AM ET Company ParticipantsDavid Tarantino - Assistant Vice PresidentKathy Powers - VP, Treasurer, and Head of Corporate Communications and Investor RelationsNeil Brinker - President and CEOMick Lucareli - EVP and CFOConference Call ParticipantsChris Moore - Senior AnalystJeff Van Sinderen - Senior AnalystMatt Summerville - Managing Director and Senior Research AnalystNoah Kaye - Senior Research AnalystBrian Drab - Partner a ...

裁员计划概述 - 博世集团计划在2030年前裁员13000人，主要影响移动出行部门 [1][2][3] - 此次裁员是继2024年裁员9000人后的进一步调整 [6] - 裁员将主要集中在德国境内的工厂，受影响地点包括斯图加特-费尔巴赫、施韦伯丁根、瓦伊布林根、比尔以及萨尔州的洪堡 [5] 裁员动因与财务目标 - 公司必须节省25亿欧元的成本，裁员是实现此目标的唯一途径 [5] - 移动出行业务存在每年约25亿欧元的成本缺口 [5] - 公司汽车业务部门的利润率目标为7%，但2024年实际利润率仅为3.8% [5] - 裁员旨在提升出行业务板块的竞争力并进行结构性成本削减 [5] 公司业绩与市场环境 - 2024年公司实现营收905亿欧元，同比下降1.2% [9] - 2024年公司息税前利润为32亿欧元，同比大跌33% [9] - 业绩下滑受欧洲供暖市场低迷、行业竞争加剧以及全球经济增长乏力影响 [9] - 电动出行等增量市场的增长速度远低于预期 [9] - 公司面临市场需求下滑、成本压力、贸易壁垒加剧以及新技术市场渗透困难等挑战 [5][9] 业务部门与成本削减措施 - 移动解决方案部门是公司最大部门，销售额占总体的59% [9] - 除裁员外，公司还计划降低材料与运营成本、缩减厂房与建筑相关投资，并精简物流与供应链 [5] - 公司在残酷的市场竞争中"为每一分钱而战" [5] 行业与宏观经济背景 - 德国8月失业人数较7月增加4.6万人，达到302.5万人，是自2015年2月以来首次突破300万大关 [9] - 德国整体环境被指不利于就业市场发展，存在官僚作风、监管负担重和税收高等问题 [10]

财务数据和关键指标变化 - 公司预计下一财年每股收益将实现高个位数增长 [6] - 第一季度价格同比上涨1%至1.5%，带来约40个基点的毛利率改善 [13] - 公司通过成本管理每年可实现1%至1.5%的净成本节约，相当于每年30至40个基点的毛利率改善 [14] - 当前毛利率较疫情前水平低约380个基点 [12] - 第一季度研发费用增速比销售额快约100个基点，但销售及行政管理费用实现了约170个基点的杠杆效益 [20] - 目标是将自由现金流转换率在2027财年前恢复到历史性的80%以上水平 [62] 各条业务线数据和关键指标变化 - 心脏消融业务目前因资本销售占比较高而对毛利率有稀释作用，但预计到2027年将转为顺风因素 [16][17] - 糖尿病业务增长快于公司整体水平但利润率较低，预计在2027年左右完成剥离，将立即带来约50个基点的毛利率提升 [15][16] - SPHER9心脏消融产品需求旺盛，公司正在建立装机基础并加快产能爬坡 [64] - 下一代SPHER360产品预计将显著缩短手术中心内操作时间至约11分钟，计划在本财年进行关键性试验 [65][66] - 肾脏去神经术业务针对美国约1800万患者群体，导管价值约16000美元，市场机会巨大 [72][73] - Hugo手术机器人系统已在美国以外30多个国家建立装机基础，预计在本日历年年底前获得FDA批准，并在第四季度开始对营收产生影响 [70][71] 公司战略和发展方向和行业竞争 - 公司战略重点是利用增长机会创造飞轮效应，将部分收益再投资于有机创新和并购，以推动下一代增长 [4][10] - 目标是通过加速增长、提高毛利率以及销售及行政管理费用杠杆来实现每股收益增长 [7][10] - 计划将研发投入占营收比例从目前的8%至8.5%提升至约10% [18][19] - 公司与Elliott Management达成建设性合作，并据此在董事会新增两名成员，并设立专注于增长和运营的专门委员会 [39][40][41][42] - 公司计划在2026年中公布新的中期计划，包括修订后的财务算法和关键绩效指标 [47] - 并购策略重点瞄准商业化前或刚商业化的公司，交易规模在10亿至40亿欧元之间，寻求在商业、研发或供应链方面的协同效应 [51][52][53][54] - 在数字手术领域，公司通过Hugo机器人及AI等构建生态系统，旨在提升在普通外科领域的竞争力并增强客户粘性 [68][69][70] 管理层对经营环境和未来前景的评论 - 公司认为其增长即将迎来拐点，增速将在下半年加速 [3][4] - 公司在定价方面已从过去持续失价转变为每年实现净涨价，得益于更好的合同管理和创新产品的差异化 [13] - 为应对外汇波动，公司对高波动性市场要求管理层通过涨价抵消贬值影响，并将对冲期限从三年缩短至两年 [23][24][25] - 公司在运营执行方面已有显著改善，过去10-12个季度未出现供应链意外，并通过集中制造和采购等举措加强了纪律 [29][30][31] - 公司认为已解决了大部分供应链和质量问题，为重新积极进行并购奠定了基础 [50][51] - 肾脏去神经术被认为是公司几十年来最大的市场机遇，预计其放量速度将快于WATCHMAN产品，后者在五年内达到50亿美元规模 [72][74][75] 其他重要信息 - 公司拥有非常强劲的资产负债表和超过50亿欧元的自由现金流，有能力在不影响股息政策的情况下进行有意义的并购 [59][60] - 公司正通过减少供应商数量、优化制造足迹和产品设计降本等措施持续改善运营 [32][33][34] - 在心脏消融市场，公司的目标是成为市场领导者，并对现有产品和管线充满信心 [63][66] - 对于肾脏去神经术，公司将进行直接面向消费者的营销以提高疗法认知度 [73] 问答环节所有提问和回答 问题: 新任CFO入职六个月的初步体会以及对股东价值创造的计划 - 回答要点包括公司增长即将迎来拐点，以及其个人在帮助提升利润率方面的作用 [3][4][5] 问题: 对实现高个位数每股收益增长的承诺和可见性 - 回答强调这是基于详细分析的承诺，并阐述了通过加速增长、提高毛利率和销售及行政管理费用杠杆来实现的算法 [6][7][10] 问题: 毛利率提升的具体路径 - 回答详细说明了当前毛利率与疫情前的差距，以及通过定价改善、成本节约来抵消业务结构带来的不利影响，并预计从2027年开始可持续改善 [12][13][14][15][16][17] 问题: 销售及行政管理费用杠杆与研发投入增加的平衡 - 回答指出计划增加研发投入，但将通过销售及行政管理费用的节约（主要在一般行政费用方面）来抵消，并保护销售费用以抓住增长机会 [18][20][21] 问题: 外汇管理方式的改变 - 回答介绍了通过成本基础匹配、要求高波动市场以涨价抵消贬值以及缩短对冲期限等策略 [23][24][25] 问题: 如何提升业务预测和执行的纪律性与可见性 - 回答提到了已实施的措施，如改变激励体系、集中关键运营职能、推行统一绩效管理系统等，并指出仍有改进空间 [28][29][30][31][32] 问题: 运营改进措施的时间框架 - 回答指出有些是中期工作，如制造足迹优化；有些是短期机会，如供应商和SKU精简；改进将持续进行 [33][34] 问题: 与Elliott Management合作的背景和影响 - 回答说明双方在加速增长、提升利润率、增加董事会专业知识和设立专门委员会等方面观点一致，合作加速了某些决策 [37][38][39][40][41][42][43] 问题: 新设立的董事会委员会将如何增加价值 - 回答认为新董事在并购、组合管理以及运营优化方面的经验将对公司有所帮助 [45][46] 问题: 2026年中计划的预期内容 - 回答暗示将包括对下一代增长的投资规划以及可能修订的财务算法和关键绩效指标 [47] 问题: 并购策略的重新活跃以及平衡早期并购与每股收益增长 - 回答解释了重新关注并购的原因，明确了目标交易类型和规模，并强调并购带来的稀释必须在公司每股收益增长承诺的可控范围内 [50][51][52][57][58] 问题: 自由现金流改善计划 - 回答驳斥了股息影响投资的看法，指出公司现金流强劲，并计划通过运营利润率提升和营运资本管理来改善现金流 [59][60][61][62] 问题: 心脏消融业务的市场机会和竞争定位 - 回答表达了成为市场领导者的雄心，并介绍了现有产品和下一代产品的进展 [63][64][65][66] 问题: Hugo手术机器人系统的进展和预期营收影响 - 回答阐述了其战略重要性在于构建生态系统，并给出了在美国获批和产生营收影响的时间表 [68][69][70][71] 问题: 肾脏去神经术业务的机会和增长预期 - 回答强调了其巨大的市场潜力、即将到来的医保支付决定以及计划中的市场教育措施，并预计放量将快于同类产品 [72][73][74][75]

[角色] 你是一名拥有10年投资银行从业经验的资深研究分析师，专门负责上市公司、行业研究。你擅长解读公司财报、行业动态、宏观市场，发现潜在的投资机会和风险。 [任务] 你需要仔细研读一份上市公司或者行业研究的电话会议记录，请阅读全文，一步一步思考，总结全文列出关键要点，不要错过任何信息，包括： * 纪要涉及的行业或者公司 * 纪要提到的核心观点和论据 * 其他重要但是可能被忽略的内容 如果没有相关内容，请跳过这一部分，进行其他的部分。 总结时要全面、详细、尽可能覆盖全部的内容、不遗漏重点,并根据上述方面对内容进行分组。 要引用原文数字数据和百分比变化,注意单位换算(billion=十亿,million=百万,thousand=千)。 [注意事项] 1) 使用中文,不要出现句号 2) 采用markdown格式 3) 不使用第一人称,以"公司"、"行业"代替 4) 只输出关于公司和行业的内容 5) 在每一个关键点后用[序号]形式引用原文档id 6) 一个[序号]只应该包含一个数字，不能包含多个，如果多个就用[序号][序号]分开写，不要写成 [序号-序号] 7) 每个关键要点后边的 [序号] 不要超过 3 个 Content: --------- <doc id='1'>QuidelOrtho (NasdaqGS:QDEL) 2025 Conference September 10, 2025 03:10 PM ET Speaker0 Go ahead and get started, I'm Katherine Schulte, I cover life sciences and diagnostics here at Baird. Very excited to have Quidel Ortho joining us today. From the company we have the CFO, Joe Buske. So Joe, thanks so much for joining us. I think we're gonna dive right into Q and A so if anyone has a question, feel free to send them to session3rwbear dot com and I will pass them along.</doc> <doc id='2'>So Joe, thought maybe we could just start at a high level. Can you just talk about key takeaways from the quarter and maybe how your strategic vision for the company is unfolding here? Speaker1 Sure. And by the way, thanks, Katherine. Thanks for having us to the conference. It's been great. And as far as that first question on highlights from Q2, I would say that we've now had two good quarters in a row to start off 2025 with good margin improvement of 400 plus basis point margin improvement over the prior year.</doc> <doc id='3'>I think we also showed that we've made some strategic decisions in line with what Brian and I said we were wanna do fifteen months ago when he started. And, examples of that would be we we announced that we're closing a very large manufacturing facility in Raritan, New Jersey, which is gonna provide some real nice operating margin improvement in a couple years. And we made the decision to pivot from Savannah development of molecular product to Lex, which is a business in UK that we're going to purchase once they get FDA approval for their first respiratory panel. And so again these decisions are just all around margin improvement and making the company more productive and more efficient. Again, things that Brian and I said we were gonna do last year when he when he started.</doc> <doc id='4'>I guess the last thing I'd mention is that the base business continues to grow in at the rate which we said it would grow, you know, in that sort of mid single digit growth for labs and immunohematology.</doc> <doc id='5'>Speaker0 Yeah, I want to get into Lexin a bit, but maybe starting on the lab side of the business. You know, to your point, recurring revenue growth remained solid to start the year. You know, where do you think you're winning in the clinical chemistry business? Speaker1 Yeah, the strategy with labs continues a strategy that was started probably about five or so years ago, and that is to focus on the small to mid size hospital and labs, which we define as our sweet spot. You know, we're doing quite well there. I would say the other strategy is to focus on leading with integrated analyzers that runs both routine chemistry and immunoassays. And, you know, that strategy continues to be the one that we're gonna employ and it's it's working quite well. And, you know, the growth in the labs business continues to be right where we said it would be in that mid single digit growth range.</doc> <doc id='6'>Speaker0 What about on the instrumentation side? You know, how's the current capital equipment environment? Speaker1 Yeah, I don't see a lot of impact of customers pausing on placing analyzers due to the macro. And I think it's mainly because the the value of the analyzers we're placing is much less than, say, an MRI or imaging piece of equipment that's, you know, millions and millions of dollars. I think I think our purchase the equipment purchases that our customers are making kind of fly below the radar to some extent. We also offer, like our competitors do, an alternative to to buying an instrument, and that is a reagent rental where we can place an analyzer at a customer location and charge them the cost of the box over the life of the contract in the form of a surcharge on the consumables. So that's a way of kind of getting around maybe CapEx limitations that a customer may have.</doc> <doc id='7'>Speaker0 And how important is the automation element to customers? You know, how has your integrated analyzer kind of helped in this environment? And I think it's around a third of your installed base now, so how do you think that will track over time? Speaker1 Yeah, for sure automation and the integrated analyzers are super important to our customers and to our strategy of growing the labs business. In fact, you look at the automation, or I should say the growth in the automation and installed base over the last several years, it's typically been in the high single digits and low double digits as indicative of the strategy working. You know, we continue to lead with that integrated analyzer which is going to drive more higher margin immunoassay revenue growth for us. And that's important because if you look at our business relative to where the market is, our mix of immunoassay and routine chemistry is inverted from where the overall market is. And so there's lots of room for us to grow that immunoassay side of the business.</doc> <doc id='8'>And in fact, if you look at our percentage of installed base that's integrated versus nonintegrated, if you go back to when Ortho Clinical Diagnostics went public in 2021, we were around 24% of the base was integrated, and now we're sitting at around 30% of that base, installed base, being integrated. So you can kind of get a feel for the pace of which we're moving and employing that strategy and you can also get a feel for how much room is left to run, how much we can run this strategy out. There's plenty of runway left.</doc> <doc id='9'>Speaker0 And in terms of that kind of immunoassay mix, I guess where do you see the biggest opportunities in the portfolio to keep driving that? Speaker1 Yeah, good question. I think that if you look at where the labs growth is, you know, in the more developed markets of The US and Western Europe, you'll see more, you know, low to mid single digit growth. But when you look in less developed areas like Latin America and Asia Pacific and Eastern Europe, you'll see more high single digits, sometimes low double digit growth. And so we I I look towards those lesser developed markets of Eastern Europe and Asia Pac as the areas where I think there's lots of opportunity for us to to grow that integrated analyzer base and grow that immunoassay business.</doc> <doc id='10'>Speaker0 And if we move on to molecular, you know, how does the planned Flex acquisition kind of expand your footprint there and maybe talk through the strategic rationale for pursuing that route instead of continuing with Savannah.</doc> <doc id='11'>Speaker1 Yeah, it was a really tough decision that we made back in June to pivot from developing Savannah to Lex. Savannah had been a product that Quidel had been working on prior to the combination with ortho for many years and it's it's it's a great product. Savannah, I think, has a lot of potential competitive advantages in the marketplace, but Lex also has some very distinct competitive advantages in the marketplace where we intend to sell it and those advantages I would say are focused on turnaround time, ease of use and cost. And so the decision was made to pivot to Lex primarily because if you look at the amount of time it would take to fill out the menu, the amount of cost it would take to fill out the menu, and the level of technical risk, which is much less in a product like Lex, we decided to discontinue Savannah and focus our resources on Lex because again, we think we can get that menu filled out much faster and for much less cost and a lot less risk. And so we believe that the first panel which was submitted to the FDA which is a respiratory panel in June, we believe that we will get approval for that panel sometime later this year.</doc> <doc id='12'>Speaker0 And maybe what's the timeline for menu expansion there into other respiratory or women's health applications? Just curious, you know, how much there is an opportunity outside of that initial panel.</doc> <doc id='13'>Speaker1 Yeah, there's lots of opportunity to fill out that menu. I think first we'll focus on RSV and strep being added to the panel and then women's health and STI will be next. More to come on specific timelines but yeah, there's plenty of opportunity to fill up that menu and expand.</doc> <doc id='14'>Speaker0 And how do you think about, you know, the overlap with kind of the rest of your portfolio? Is there any potential cannibalization for Sofia? Speaker1 The good news is is that the Lex product can be commercialized through the existing sales force. So there's no need to add any resources to commercialize Lex as we move into early twenty six. They're based on the customer research that we've done, the KOLs we've talked to, we believe there's plenty of room for both a rapid antigen test like Sofia and a molecular product like Lex. And there is some some overlap but I would say it's not not significant at all. It's probably, you know, 10% or less of of overlap and and even that amount of overlap is not overly concerning for us because if there are customers who'd rather use Lex rather than Savannah, the Lex margins are higher.</doc> <doc id='15'>And so that would be some minor amounts of cannibalization that I'd probably welcome from a margin perspective.</doc> <doc id='16'>Speaker0 And you've talked about kind of reinvesting some of your Savannah dollars into Lex, you know, where are those investments mainly concentrated this year and kinda what additional steps are you taking to prepare for that kind of limited commercial launch in the first half of next year? Speaker1 Yeah, we're definitely excited about getting approval on that first panel later this year so we can start a limited commercialization in this first and second quarter twenty six respiratory season. As I said a minute ago, really no need for any additional commercial resources. We've got everything we need. Being the leader in respiratory testing in The US, we've got all the commercial resources that we need to sell that product. I guess the most near term investments might be in the form of not too significant CapEx that will be needed to increase the manufacturing capacity for Lex.</doc> <doc id='17'>There is a line that the company has in The UK right now but will need an additional line either somewhere in The UK again or in The US. Haven't decided that yet but that will be something that will stand up pretty early in '26 so that we can hit the late in the '26, early twenty seven respiratory season with a much more fulsome rollout and commercialization.</doc> <doc id='18'>Speaker0 Okay. And then on point of care, you you lowered the 2025 outlook for COVID revenue coming out of the second quarter. Can you just remind us of the seasonality baked in for the third and fourth quarter and maybe just given the trends that you've seen so far this year, you know, how you think about forecasting, you know, endemic COVID revenues longer term? Speaker1 Yeah. COVID's been been quite the ride. And I I know that there's been a lot of focus on the on the decline of the COVID revenue over the last several years, but I do believe that as a headline conclusion, we've digested most of that decline. When you think about where we were in '21 and '22 with a billion 4 of COVID revenue that's dropped to 400,000,000 and then a 185,000,000 last year, you know, the guidance this year is for 70 to a 100. And if you just pick the midpoint of of that, somewhere you in the mid eighties, I think that's a realistic, very realistic point of of where where the declines end.</doc> <doc id='19'>And, you know, and I can say that with with some confidence because all of the the government order revenue is is gone and the retail business is is fairly small at this point. There's not a whole lot lot left. So most of what's left is the professional use space revenue which has proven to be somewhat consistent and durable. And so we do think that that, you know, call it that midpoint of the 70 to a 100 is probably a good place to think that not only we're gonna end up this year, but where we're gonna go for the next next several years with COVID revenue. So I think all of these views of revenue of ex COVID that we've done for the past couple years, think we're we're really getting to the end of that, which is great news, I know, the buy side and sell side.</doc> <doc id='20'>Speaker0 Yep. Absolutely. Maybe any thoughts on the upcoming flu season? Are there any clues from the Southern Hemisphere around, you know, what this upcoming season could look like relative to historical trends? Speaker1 Yeah. The flu season in the Southern Hemisphere is always a good data point for us and that flu season has turned out to be one that I would define as more typical or average. And so that's good because that's what we've said all along this year is that our guidance for flu revenue is gonna be a typical or average season. And we define that as flu season in terms of volume, 50 to 55,000,000 tests, and the combo test mix being greater than 50% and steady market share. So the new model that we've gone to to project the flu revenue that we went to in '24 has proven out to be a good one.</doc> <doc id='21'>You know, we very close, almost I would say spot on to what we guided the street to for the first half of the year for flu revenue. And so we have a lot of confidence that where we are for the second half of this year is going to be pretty close as well. And and, you know, what we're seeing is that the the patterns for the flu season are getting back to more predictable pre pandemic patterns. The the level of testing is up versus pre pandemic mainly because of the combo test, and we think that combo test is pretty durable given that it's been over 50% of our flu revenue now for two plus years. And so, you know, I think that flu season is, the flu season revenue is getting a little more predictable.</doc> <doc id='22'>So we feel good about where the guidance is for the second half of the year.</doc> <doc id='23'>Speaker0 Yeah. Maybe shifting to transfusion medicine, you know, how should we think about that business following the U. Donor screening wind down and, you know, what's your view on the growth outlook there? Speaker1 Yeah, so as a reminder, the transfusion medicine business unit for us is comprised of the donor screening business, which is primarily the business of screening for infectious disease in the blood supply donations. And we decided to shut down, wind down that business last year because it is a small market, It's lower growth and it's it's got lower margins compared to the rest of our businesses. So we decided to wind it down last year. And, you know, last year we did about a 120,000,000 of revenue. This year it'll be probably 40 to 50,000,000 of revenue.</doc> <doc id='24'>And this business will be fully wound down in early twenty six. And so again, that revenue headwind of the donor screening wind down, which we've had all year, which is down about 40% in the first half of the year, that headwind will go away in the first half of next year and we won't be dealing with that anymore. And the top line revenue growth will be made up more of the base business, which we see as a mid single digit growth business. The other business within transfusion medicine is immunohematology, and that's a business that we really like. That business is global.</doc> <doc id='25'>We're the global number one in terms of market share with that business and we do intend to continue to invest in that business going forward.</doc> <doc id='26'>Speaker0 Yeah. Okay. And maybe on China, there's been a lot of noise there for diagnostics companies, particularly this quarter. It sounds like you've been relatively insulated from some of the unbundling and VBP headwinds that</doc> <doc id='27'>others are seeing. Is that right? And are there any parts of your business that are seeing pressure there? Speaker1 I was waiting for the China questions. I knew they were coming. The we spent a lot of time on this on our last earnings call. Brian, I think, did a great job of of talking about why our business is different from others in our space in in China. And I know a lot of folks like to paint a broad brush with with the China risk, but our business is different, and here's why.</doc> <doc id='28'>First of all, we use a dry slide technology on our lab side, which none

财务数据和关键指标变化 - 第二季度净销售额为2.143亿美元 同比增长1.9% 去年同期为2.102亿美元 [8] - 可比销售额增长2.5% 连续第五个季度实现正增长 [2][8] - 北美净销售额1.8亿美元 同比增长2.1% 国际净销售额3420万美元 同比增长1% [8] - 毛利率为35.5% 同比提升130个基点 主要受产品利润率改善60个基点和经营杠杆60个基点推动 [10] - 营业利润为10万美元 占净销售额0.1% 去年同期为营业亏损40万美元 [11] - 净亏损100万美元 每股亏损0.06美元 去年同期净亏损80万美元 每股亏损0.04美元 [11] - 现金及有价证券1.067亿美元 去年同期为1.27亿美元 [13] - 库存1.577亿美元 同比下降0.6% [14] 各条业务线数据和关键指标变化 - 女装品类表现最佳 其次是硬商品和配件 鞋类和男装表现相对较弱 [9] - 私有品牌销售额占比达到30% 创历史新高 去年同期为27% [4] - 可比销售额增长主要由单笔交易金额增加推动 交易笔数有所下降 [9] - 第三季度至今所有品类均实现正可比销售增长 女装领先 其次是男装、配件、鞋类和硬商品 [16] - 私有品牌产品利润率比品牌产品高10-15个百分点 [55] 各个市场数据和关键指标变化 - 北美可比销售额增长4.2% 连续第六个季度正增长 [9] - 国际可比销售额下降5.5% 2025年以来持续为负 [9] - 北美业务是主要增长动力 8月份实现两位数可比销售增长 [3] - 按固定汇率计算 国际净销售额下降4.2% [8] - 第三季度至今北美可比销售额增长13% 国际下降3.2% [16] 公司战略和发展方向和行业竞争 - 专注于三大战略重点：客户导向的收入增长、盈利能力优化、利用财务基础管理波动 [3][5] - 2024年引入超过120个新品牌 持续提供独特和独家商品 [4] - 坚持高端定价策略 支持利润率提升和市场份额扩张 [5] - 欧洲市场面临挑战 正在执行三年计划使其恢复盈亏平衡 [42] - 计划2025年新开6家门店 关闭约20家门店 [20] - 资本支出预计1.1-1.3亿美元 低于2024年的1500万美元 [20] 管理层对经营环境和未来前景的评论 - 对北美业务韧性表示满意 但对关税和消费者不确定性保持谨慎 [3][17] - 8月份可比销售额增长11.2% 两年叠加增长23.3% 为重要假日季提供信心 [3][15] - 预计2025年销售额增长3-4% 尽管门店关闭将带来约1400万美元负面影响 [19] - 预计产品利润率将实现温和同比增长 在2024年改善70个基点基础上进一步提升 [19] - 预计2025年将恢复盈利 营业利润率和净利润将同比增长 [20] 其他重要信息 - 第二季度回购60万股 平均成本13.10美元 总额780万美元 [14] - 截至8月2日 仍有720万美元回购额度 [14] - 预计2025年有效税率50-60% 稀释后股数约1730万股 [20][21] - 欧洲最大市场德国经济基本零增长 期待2026年经济刺激计划带来改善 [44] 问答环节所有提问和回答 问题: 第三季度指引假设及经营利润率构成 [23] - 假设季末可比销售额将回落至低个位数增长 接近第二季度水平 [24] - 预计将获得显著的毛利率扩张 包括经营杠杆和产品利润率改善 [25] - SG&A费用增长率预计将低于销售额增长率 第三季度将获得良好杠杆 [25][26] 问题: 平均单价(AUR)增长驱动因素 [27] - AUR增长是价格上调、品类组合变化和促销策略共同作用的结果 [28] - 私有品牌业务采取了价格调整 同时品类向服装业务转移 [28] - 过去五个季度增长主要由AUR推动 返校季期间交易笔数也有所增加 [29] 问题: 私有品牌强势表现及牛仔品类占比 [30] - 私有品牌在牛仔等核心裤类品类中渗透率较高 [31] - 增长反映了品牌周期加快的趋势 公司需要更深度掌控核心品类 [32] - 通过多个品牌针对不同客群细分 坚持高端定价策略 [33] 问题: 长期经营利润率目标及驱动因素 [38] - 长期目标仍是恢复到高个位数营业利润率水平 [40] - 关键是销售额恢复 北美业务仍有增长空间回到2019年水平 [41] - 产品利润率提升和国际业务改善将是重要驱动因素 [42] 问题: 欧洲业务面临的主要挑战 [44] - 需要当地经济环境配合 特别是德国市场需要恢复增长 [44] - 必须优化商品组合 更好地把握流行趋势 [45] - 需要提升门店体验 增加销量和钱包份额 [45] 问题: 滑板和鞋类业务是否已触底 [50] - 滑板硬件业务已转正 但对持续性保持谨慎 通常春夏表现更好 [51][52] - 鞋类业务仍然充满挑战 不仅仅是单一品牌的问题 [53] - 相信滑板业务已触底 但鞋类业务仍需时间调整 [54] 问题: 产品利润率机会与私有品牌关系 [55] - 私有品牌产品利润率比品牌产品高10-15% [55] - 但也通过授权模式与品牌合作 利润率介于两者之间 [56] - 历史上在品牌周期中也实现过产品利润率提升 [55]

财务数据和关键指标变化 - 研发费用占销售额比例从8%提升至9%-10% 且不会影响每股收益 [11] - 第一季度毛利率改善30-40个基点 主要由定价和成本节约推动 [36] - 预计2027财年实现高个位数每股收益增长 由收入增长和运营杠杆驱动 [38][54] - 外汇因素预计在2027财年继续提供小幅顺风 [58] - 现金转换率将从2027年开始改善 [26] 各条业务线数据和关键指标变化 - 心脏消融解决方案(CAS)业务增长从30%加速至近50% [59] - 糖尿病业务将推出两个新传感器(Instinct和Simpler)和新款耐用泵 [49][51] - TAVR业务全球增长第四季度为10% 第一季度为6%以上 [83] - 骨盆健康业务将推出胫骨神经刺激器 预计将带来显著增长 [48][86] - 神经血管业务正在推出颈动脉支架和出血性产品 [47] 各个市场数据和关键指标变化 - 美国TAVR增长低于国际市场的表现 [83] - 日本市场特别重视安全性 Pulse Select和Afera系统因安全性领先而受到青睐 [68] - 全球手术机器人市场规模达60亿美元 [42] 公司战略和发展方向和行业竞争 - 与Elliott Management存在大量战略共识 重点为"资本化"和"加速" [5] - 计划通过补强并购和持续组合审查来加速加权平均增长率提升 [6] - 专注于高增长领域进行并购 如心脏消融、结构性心脏病和高血压 [19][21] - 糖尿病业务分拆正在进行中 预计明年下半年完成 [30] - Hugo手术机器人系统是重大投资 公司对其长期潜力保持信心但会定期评估里程碑 [40][43][44] - 目前心脏消融市场份额约为10% 但有信心通过Afera等产品成为市场领导者 [66] 管理层对经营环境和未来前景的评论 - 公司运营基础(IT、供应链、质量)已显著改善 [88] - 创新产品收入占比(活力指数)从几年前的十几%提高到现在的20%中段 并预计将继续增长 [35] - Ardian的NCD覆盖范围比许多投资者预期的更广泛 最终决定预计在10月8日左右 [71][74] - Ardian的采用曲线预计将比Watchman更快 预计规模也将更大 [80] - 对下半年的增长加速充满信心 由多种增长驱动因素推动 [47][48] 其他重要信息 - 定价改善由三个因素推动：更好的外汇管理、更好的折扣控制和创新产品推出 [33][34] - 成本节约由严格的采购和工厂绩效管理推动 [36] - Afera系统需求非常高 目前存在产能限制但正在增加生产线 [64][65] - Ardian的培训负担较低 重点在于市场开发和建立转诊路径 [76][77] 问答环节所有的提问和回答 问题: 与Elliott Management的共识领域及改进方向 - Elliott以创造股东价值著称 其研究深入且与公司存在大量共识 改进重点在于加快组合优化步伐(包括并购) [5][6] 问题: 投资组合广度是否影响增长及是否会进一步分拆 - 研发占销售额比例目标提升至9%-10% 同时进行补强并购 公司相信能管理好当前组合并实现增长 但也不排除任何可能性 [11][12][14] 问题: 电池等技术共享是否阻碍业务分拆 - 这增加了额外障碍 但糖尿病业务因协同效应较少而更容易分拆 若有需要 公司不会让此类问题阻碍分拆决策 [16][17] 问题: 并购活动少于同行的原因及未来展望 - 过去因COVID-19、供应链和产品质量问题而更专注于夯实运营基础 现在处于更有利位置进行并购 重点关注高增长领域 [18][19] 问题: 股息支付率和稀释效应是否制约并购 - 股息不构成问题 公司有足够火力进行规模可观的补强并购 现金生成能力改善也将提供支持 对于战略性交易 可接受短期稀释 [24][25][27] 问题: 如何改善毛利率 - 短期不利因素(关税、产品组合压力)将逐步缓解 运营改善(定价、成本节约)持续进行 预计能实现持续的毛利率改善 [29][30][32][36] 问题: 对Hugo手术机器人投资回报的看法 - 该投资巨大且竞争激烈 但公司相信其系统及围绕它的整体业务模式(包括数字平台和其他技术)将提升业务的整体盈利能力 [40][41][42] 问题: 第一季度多个业务表现疲软但全年增长指引是否保守 - 公司对下半年增长加速充满信心 由多种增长驱动因素推动 但目前维持原有指引 [47][48] 问题: 糖尿病业务是否会改善 - 将推出两个新传感器和新款耐用泵 业务前景令人兴奋 [49][51] 问题: 2027财年增长加速及每股收益增长的驱动因素 - 增长驱动因素将发挥全年效应 运营杠杆持续 线下项目压力减轻 共同推动高个位数每股收益增长 [54][56][57] 问题: CAS业务增长加速的驱动因素及未来展望 - 增长主要由Afera系统及其导管驱动 需求旺盛且供应能力正在提升 [59][60][65] 问题: 是否有机会成为心脏消融市场领导者 - 公司相信有机会 凭借Afera、Pipeline产品(如SPHERI-nine导管)和卓越的安全性数据 但未给出具体时间表 [66][68] 问题: 对Ardian的NCD覆盖范围及最重要变更的看法 - 覆盖范围良好且符合预期 目前重点转向市场开发和建立转诊路径 [71][74][77] 问题: 对Ardian规模采用曲线的看法(与Watchman对比) - 预计规模更大且采用速度更快 [80] 问题: 美国TAVR业务表现 - 第一季度增长较弱但第四季度强劲 需综合看待 全球业务表现良好且公司对其地位充满信心 [83][84] 问题: 其他未讨论的重要事项 - 胫骨神经刺激器即将推出 预计将带来显著增长 公司运营基础稳固 增长驱动因素就绪 处于进攻态势 [86][88]

投资评级 - 维持"买入"评级 [5][9] 核心财务表现 - 2025H1收入25.93亿元 同比+27.0% [2] - 2025H1经调整净利润9142万元 同比+79.6% [2] - 2025H1经调整EBITDA 3.23亿元 同比+38.3% [2] - 经调整EBITDA利润率12.4% 同比+1.0个百分点 [4] - 经调整净利率3.5% 同比+1.0个百分点 [4] - 餐厅层面经营利润率14.6% 同比+0.1个百分点 [4] 扩张进展 - 截至2025H1门店总数1198家 较2024年末净增190家 [3] - 完成全年300家开店计划的63.3% [3] - 已入驻48个城市 上半年新拓9城 [3] - 截至8月15日门店较上半年额外净增43家 另有27家在建 35家已签约 [3] 运营指标 - 2025H1同店销售额同比-1.0% [3] - 单店日均销售额12915元 同比-4.44% [3] - 原材料成本占比27.25% 同比-0.07个百分点 [4] - 员工成本占比27.7% 同比+0.3个百分点 [4] - 租金相关开支占比9.99% 同比+0.11个百分点 [4] 盈利预测 - 预计2025年收入55.24亿元 同比+28.05% [5][8] - 预计2026年收入71.13亿元 同比+28.77% [5][8] - 预计2027年收入89.67亿元 同比+26.06% [5][8] - 预计2025年经调整净利润2.1亿元 同比+61% [5] - 预计2026年经调整净利润3.5亿元 同比+66% [5] - 预计2027年经调整净利润5.7亿元 同比+62% [5] 财务比率预测 - 预计2025年ROE 6.13% 2026年11.11% 2027年16.34% [8] - 预计2025年P/E 45.37倍 2026年27.30倍 2027年16.88倍 [8] - 预计毛利率稳定维持在73%水平 [10]

行业投资评级 - 纺织服饰行业投资评级：优于大市（维持）[1] 核心观点 - 亚玛芬体育2025年第二季度收入同比增长23%至12.36亿美元，调整后净利润同比增长46%至0.36亿美元，均超彭博一致预期及公司指引[2] - 萨洛蒙品牌、DTC渠道、大中华及亚太地区表现突出，带动收入增长，管理层上调全年收入及EPS指引[2][3] - 经调毛利率达58.7%，创历史新高；经调营业利润率同比提升250bps至5.5%，显著高于指引[5][6] 业绩表现 收入与利润 - 2025年上半财年收入同比增长23%至27.09亿美元，调整后净利润同比增长146%至1.84亿美元[2] - 2025Q2收入同比增长23.5%（固定汇率+22%），其中DTC渠道收入占比提升至52%（同比+40%）[5][12] - 分业务收入：Technical Apparel（始祖鸟主导）+23.5%，Outdoor Performance（萨洛蒙主导）+35.3%，Ball & Racquet（威尔胜主导）+10.7%[5][8][11] 利润率与费用 - 经调毛利率同比提升250bps至58.7%，主要受益于渠道/地域/产品组合优化及折扣减少[6] - 经调营业利润率同比提升250bps至5.5%，其中Outdoor Performance业务利润率提升720bps至5.1%[6][11] - 财务费用率同比下降270bps至1.8%，因债务结构优化及外汇收益抵消利息支出[6] 业务与区域表现 分业务 1. **Technical Apparel**： - 始祖鸟驱动全渠道增长，鞋类与女性产品表现突出，亚太地区增速领先[8] - 营业利润率13.9%（同比-10bps），受零售扩张导致的SG&A费用增加影响[8] 2. **Outdoor Performance**： - 萨洛蒙鞋类加速放量，大中华区新开16家门店，全年目标290家[11] - 营业利润率由负转正至5.1%，受益于成本优化与DTC渠道杠杆效应[11] 3. **Ball & Racquet**： - 威尔胜网球360系列表现强劲，服装收入增长超100%[11] 分地区 - 大中华区收入同比+42%（远超彭博预期），亚太地区+45%，北美+6%，EMEA+18%[5][12] 管理层指引 - **全年指引上调**： - 收入增速从15-17%上调至20-21%（汇率贡献100bps）[20] - 经调EPS从0.67-0.72美元上调至0.77-0.82美元[20] - **分业务指引**： - Technical Apparel收入增速上调至22-25%（原20-22%）[22] - Outdoor Performance利润率指引上调至11-11.5%（原约9.5%）[22] 投资建议 - 亚玛芬体育业绩全面超预期，安踏体育（持股41.97%）有望受益于联营公司盈利贡献提升[24] - 可比公司估值显示亚玛芬2025年PE为50倍，低于耐克（35.3倍）但高于安踏（19.0倍）[25]